VisseR., NagaseH.Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res2003; 92: 827–39.
2.
CastroM.M., Tanus-SantosJ.E.Inhibition of matrix metalloproteinases (MMPs) as a potential strategy to ameliorate hypertension-induced cardiovascular alterations. Curr Drug Targets2013; 14: 335–43.
3.
YongV.W., PowerC., ForsythP.Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci2001; 2: 502–11.
4.
SilbersteinS.D.Migraine. Lancet2004; 363: 381–91.
5.
Martins-OliveiraA., SpecialiJ.G., DachF.Different circulating metalloproteinase profiles in women with migraine with and without aura. Clin Chim Acta2009; 408: 60–4.
6.
LeiraR., SobrinoT., Rodriguez-YanezM.MMP-9 immunoreactivity in acute migraine. Headache2007; 47: 698–702.
LeungM.C., YipK.K., HoY.S.Mechanisms underlying the effect of acupuncture on cognitive improvement: a systematic review of animal studies. J Neuroimmune Pharmacol2014; 9: 492–507.
GoncalvesF.M., Martins-OliveiraA., LacchiniR.Matrix metalloproteinase (MMP)-2 gene polymorphisms affect circulating MMP-2 levels in patients with migraine with aura. Gene2013; 512: 35–40.
13.
Martins-OliveiraA., GoncalvesF.M., SpecialiJ.G.Specific matrix metalloproteinase 9 (MMP-9) haplotype affect the circulating MMP-9 levels in women with migraine. J Neuroimmunol2012; 252: 89–94.
14.
GerlachR.F., DemacqC., JungK.Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem2007; 40: 119–23.
